Results 211 to 220 of about 155,269 (289)

The power of many: when genetics met yeasts and high‐throughput

open access: yesBiological Reviews, EarlyView.
ABSTRACT In recent years, complex technological capabilities have evolved, driven by the need to solve complex and integrative biological questions through global analyses. New equipment allows the scaling up and automation of processes which previously were carried out on a very limited scale.
Víctor A. Tallada, Víctor Carranco
wiley   +1 more source

Correction: Cross-species translational modelling of targeted therapeutic oligonucleotides using physiologically based pharmacokinetics. [PDF]

open access: yesJ Pharmacokinet Pharmacodyn
Derbalah A   +8 more
europepmc   +1 more source

Pd(II)‐Catalyzed Strategies for the β‐Arylation of α‐Amino Acids: An Overview

open access: yesChemistry – A European Journal, EarlyView.
The graphical abstract summarizes the review “Pd(II)‐Catalyzed Strategies for the β‐Arylation of α‐Amino Acids: An Overview”, highlighting representative Pd(II)‐catalyzed methods for the β‐arylation of α‐amino acids. Key mechanistic features, substrate diversity, and synthetic relevance of these transformations are showcased. Abstract Metal‐catalyzed C─
Davide Illuminati   +4 more
wiley   +1 more source

Living Microbial Drugs

open access: yesChemistry – A European Journal, EarlyView.
The introduction outlines the review scope. Microbial cell factories as living drugs cover host–gut microbiota, bacteria, yeast, and other microbial systems, with comparative host advantages. Engineering strategies include synthetic circuits, quorum sensing, and memory.
Cemile Elif Özçelik   +3 more
wiley   +1 more source

Strain Release of 1‐Azabicyclo[1.1.0]butanes as a Gateway to Highly Functionalized Azetidines: New Strategies and Structural Motifs

open access: yesChemistry – A European Journal, EarlyView.
Over the past decade, the interest in azetidines has continuously risen, by virtue of their highly appealing pharmaceutical properties. Monocyclic, spirocyclic, and bridged azetidines can be accessed by leveraging 1‐azabicyclo[1.1.0]butanes as precursors.
Yuri Gelato   +3 more
wiley   +1 more source

Concomitant 5‐Aminosalicylic Acid Does Not Affect the Efficacy of Janus Kinase Inhibitors in Ulcerative Colitis

open access: yesClinical Pharmacology &Therapeutics, EarlyView.
We evaluated whether concomitant 5‐aminosalicylic acid (5‐ASA) influences clinical remission in patients with ulcerative colitis (UC) receiving Janus kinase inhibitors (JAKi). In this retrospective, multicenter cohort study, UC patients receiving tofacitinib (n = 181), upadacitinib (n = 313), or filgotinib (n = 139) were included.
Antonio Tursi   +100 more
wiley   +1 more source

Home - About - Disclaimer - Privacy